Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;2(2):34-37.
doi: 10.5114/ceh.2016.60247. Epub 2016 Jun 6.

Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

Joanna Pogorzelska  1 , Robert Flisiak  1
Affiliations
Review

Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

Joanna Pogorzelska et al. Clin Exp Hepatol. 2016 Jun.

Abstract

Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r ± DSV ± RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r ± DSV ± RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r ± DSV ± RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.

Keywords: HCV; dasabuvir; ombitasvir; paritaprevir.

PubMed Disclaimer

References

    1. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236. - PubMed
    1. Flisiak R, Urbánek P, Rokusz L, et al. New therapeutic options for HCV in Central Europe. Clin Exp Hepatol. 2016;1:7–11. - PMC - PubMed
    1. Halota W, Flisiak R, Boroń-Kaczmarska A, et al. Polish Group of HCV Experts. Recommendations for the treatment of hepatitis C Polish Group of HCV Experts – 2015. Clin Exp Hepatol. 2015;3:97–104. - PMC - PubMed
    1. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Efficacy and safety of paritaprevir/r/ombitasvir/dasabuvir ± ribavirin in genotype 1 HCV infected patients treated in real life settings (AMBER study) J Viral Hepatitis. 2015;22(Suppl 3):4.
    1. Flisiak R, Jaroszewicz J, Janczewska E, et al. Predictors of decompensation during ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin treatment of genotype 1 and 4 HCV infected patients (real life AMBER study) J Hepatol. 2016;64(Suppl 2):SAT–253.

LinkOut - more resources